ARS Pharmaceuticals, Inc. SPRY Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s total equity?
- ARS Pharmaceuticals, Inc. (SPRY) reported total equity of $61.31M in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s total equity changed year-over-year?
- ARS Pharmaceuticals, Inc.'s total equity decreased by 73.2% year-over-year, from $228.97M to $61.31M.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s total equity?
- Over 5 years (2020 to 2025), ARS Pharmaceuticals, Inc.'s total equity has grown at a 52.1% compound annual growth rate (CAGR), from -$14.05M to $114.26M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.